Oxford study backs mixing of Covid vaccines, no safety concerns raised

The study supports flexible use of these vaccines in primary immunisation schedules

Coronavirus vaccine, Covid-19 vaccines
Press Trust of India London
2 min read Last Updated : Dec 08 2021 | 1:11 AM IST
Following up first doses of the AstraZeneca or Pfizer vaccines with second doses of the Moderna or Novavax jabs generates robust immune response against Covid-19, according to a study published in The Lancet journal.

A team led by researchers at the University of Oxford in the UK found that no safety concerns were raised in the study of 1,070 participants.

The study supports flexible use of these vaccines in primary immunisation schedules, which is crucial to help rapidly deploy these vaccines, especially in low- and middle-income countries where vaccine supply may be inconsistent. “Thanks to studies such as these, we are now getting a more complete picture of how different Covid-19 vaccines can be used together in the same vaccine schedule,” said Matthew Snape, Associate Professor at the University of Oxford.

On Alert

Child Infections

The WHO's office for Europe said children in the 5 to 14 age group now account for the highest rates of reported Covid-19 infection in the region. WHO Europe Regional Director Dr Hans Kluge also argued that vaccine mandates should be “an absolute last resort,” and said that Covid-19 deaths remain “significantly below previous peaks.”
 
A gunman kills two people and injures four  at a Moscow government centre after being told to put on a face mask
New data shows GSK-Vir drug works against all Omicron mutations
Austria to lift lockdown but not for the unvaccinated

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusOxford UniversityCoronavirus Vaccine

Next Story